- Quantitative assay to determine the number of copies of the CBFB-MYH11 Type A rearrangement resulting from the pericentric inversion of chromosome 16 [inv(16)(p13q22)] and the number of copies of the endogenous ABL1 gene.
- It includes an endogenous control of the ABL1 gene to be able to carry out the relative quantification. In addition, it allows to confirm the quality and integrity of the sample.
- Allows detection of minimal residual disease (MD). The theoretical sensitivity level that can be achieved is MR 4 (0.01% of inv(16)(p13q22)).
- High sensitivity and specificity: The limit of quantification (LOQ) has been set at 125 total copies for both theABL1reference gene and the inv(16)(p13q22) rearrangement.
- It complies with the quality requirements specified by ISO 9001 and ISO 14001 in relation to the materials used in its manufacturing process.
- For research use.
Description
Determination of the number of copies of the CBFB-MYH11 type A rearrangement related to Acute Myeloid Leukemia (AML)
Format
48×2 rxn
Technology
real-time PCR
Reference
IMG-109
Compatible equipment
7500 FAST Real-Time PCR System (ThermoFisher), StepOnePlus Real-Time PCR System (ThermoFisher)
Real-time PCR assay employing a combination of oligonucleotides and fluorescent hydrolysis probes for relative quantification of CBFB-MYH11 Type A rearrangement copy number relative to ABL1 reference gene copy number.
- Amount of cDNA required: 20µL of cDNA resulting from the reverse transcription of 1 µg of RNA.
- Sample type: Peripheral blood (Germinal)
- Number of reactions per sample: 4
- Number of targets: 2
- Manual working time: 45 min
- Duration of the PCR program: 1h 15 min
- Compatible cyclers: Real-time PCR cycler with the FAMTM channel
Imegen-Inv16
Fill in the form to request this kit.
Call us at +34 963 212 340Or write to us at info@healthincode.com
